We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Aurinia Selects Worldwide As CRO For Phase3 Valcosporin Trial

News   Jan 31, 2017 | Original Story From Aurinia Pharmaceuticals

 
Aurinia Selects Worldwide As CRO For Phase3 Valcosporin Trial
 
 
 

RELATED ARTICLES

Making AI Less Biased

News

With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.

READ MORE

Inflammation-blocking Inhibitor Could Treat Sepsis Too

News

A new inhibitor which decreases lung inflammation could hold the key to treating Acute Respiratory Distress Syndrome and sepsis.

READ MORE

AI Predicts Treatment Effectiveness

News

A new AI method developed by Finnish researchers now provides answers about treatment effectiveness. Using modelling, the method makes it possible to compare different treatment alternatives and to identify patients who will benefit from treatment.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE